Tetraphase Pharmaceuticals Inc (TTPH) Expected to Announce Quarterly Sales of $2.23 Million

Equities research analysts predict that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will post $2.23 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from $1.60 million to $2.90 million. Tetraphase Pharmaceuticals reported sales of $2.53 million during the same quarter last year, which indicates a negative year-over-year growth rate of 11.9%. The business is scheduled to report its next earnings results on Tuesday, March 5th.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full year sales of $16.98 million for the current financial year, with estimates ranging from $16.20 million to $17.88 million. For the next fiscal year, analysts anticipate that the company will post sales of $16.71 million, with estimates ranging from $11.00 million to $31.55 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Tetraphase Pharmaceuticals.

Several research firms recently issued reports on TTPH. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. Robert W. Baird reissued a “buy” rating and issued a $3.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Monday, January 7th. Finally, B. Riley began coverage on Tetraphase Pharmaceuticals in a research note on Friday, January 4th. They issued a “buy” rating and a $3.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $5.36.

NASDAQ TTPH opened at $1.20 on Thursday. The stock has a market capitalization of $64.35 million, a P/E ratio of -0.46 and a beta of 2.89. Tetraphase Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $4.49.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Tetraphase Pharmaceuticals by 3.7% during the 2nd quarter. BlackRock Inc. now owns 4,172,314 shares of the biopharmaceutical company’s stock valued at $14,895,000 after acquiring an additional 149,866 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Tetraphase Pharmaceuticals by 9.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 275,630 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 23,337 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in Tetraphase Pharmaceuticals by 400.0% during the 3rd quarter. Canada Pension Plan Investment Board now owns 250,000 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 200,000 shares in the last quarter. Marshall Wace LLP bought a new stake in Tetraphase Pharmaceuticals during the 3rd quarter valued at approximately $927,000. Finally, Alambic Investment Management L.P. boosted its position in Tetraphase Pharmaceuticals by 392.6% during the 3rd quarter. Alambic Investment Management L.P. now owns 87,704 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 69,900 shares in the last quarter. 42.90% of the stock is currently owned by institutional investors.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Recommended Story: Conference Calls

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply